New hope for tough pancreatic cancers: drug combo aims to shrink tumors before surgery

NCT ID NCT06673017

Recruiting now Disease control Sponsor: PanTher Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is either borderline resectable or locally advanced (meaning it has not spread far but is hard to remove surgically). The goal is to see if adding PTM-101 is safe and can shrink tumors enough to allow successful surgery. About 26 participants will receive the drug during their pre-surgery treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BORDERLINE RESECTABLE PANCREATIC ADENOCARCINOMA LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA PANCREATIC CANCER PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Hoag Memorial Hospital Presbyterian
RECRUITING

Newport Beach, California, 92658, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Northwell Health Zuckerberg Cancer Center
RECRUITING

Lake Success, New York, 11042, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
Virginia Mason Medical Center
RECRUITING

Seattle, Washington, 98101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.